The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral artery (SFA) and femoropopliteal segments.
Boston Scientific’s first study compared one paclitaxel-eluting stent to other stents in treating PAD. The systematic meta-analysis sought to compare long-term Eluvia outcomes with other commonly used stents in SFA lesions over 15 years. It looked at 142 clinical trials with results for more than 52,000 patients.
Eluvia — which has been FDA-approved since 2018 — showed superior and consistent results, especially in challenging, long lesions. That included superior primary patency rates and lower target lesion revascularization (TLR) rates at both 12 and 24 months compared to three other stent technologies. The stent also showed durable vessel patency, reducing the need for repeat interventions.
Investigators concluded that Eluvia outperformed other stent technologies in maintaining vessel patency and minimizing reinterventions, according to Boston Scientific.
Separately, the TRUE PTX real-world study compared Eluvia to bare device therapies for PAD. It evaluated 12-month amputation and readmission rates in a large population. A subgroup analysis assessed outcomes in patients treated with Eluvia compared to those treated with percutaneous transluminal angioplasty (PTA) or bare metal stents (BMS).
Results showed that patients treated with non-drug-eluting therapies had 47% higher odds of above-ankle amputations. Investigators also saw a 23% increased likelihood of any hospital readmission within 12 months in the non-DES group compared to Eluvia. Eluvia significantly reduced both the risk of major amputation and hospital readmission in a real-world PAD population, Boston Scientific said.
